Oral solid dose CDMOs in Europe: 94 compared (2026)
94 of the 255 contract development and manufacturing organisations in A4BEE’s European census list oral solid dose manufacturing among their capabilities. The largest, with revenue over €1bn, are ACS Dobfar, Biofarma Group, BSP Pharmaceuticals, Catalent, Famar, Fareva and 7 more. 37 sit between €250m and €1bn and 44 are smaller or niche.
By ownership: 44 family-owned, 24 private equity, 5 listed, 19 part of a pharma or industrial group and 2 state-owned. They are spread across 26 countries, led by Italy (16), Spain (13), the United Kingdom (9), Germany (8) and Ireland (6). 53 of the 94 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
94 companies
Oral solid dose CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano, Italy | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Biofarma GroupItalian/European leader in third-party-exclusive dev, manufacture and packaging of food supplements, probiotic drugs, medical devices. | Mereto di Tomba, Italy | Private equityArdian | Tier 1 | €443.3 m | Oral solid dose | high |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| CatalentTaken private by Novo Holdings (US$16.5 bn, Dec 2024); global but with EU sites. | Somerset, NJ, United States | Part of a pharma or industrial groupNovo Holdings | Tier 1 | ~US$4.4 bn FY2024 (global) | Biologics and biosimilars, Cell and gene therapy, Oral solid dose, Sterile fill-finish | medium |
| FamarOne of Europe's largest pure-play pharma/consumer-health CDMOs; 70+ yr legacy. Sterile injectables, eye drops, syrups, solids. 80 markets. | Alimos, Greece | Private equityMidEuropa | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| HemofarmSTADA's largest manufacturing hub with a contract-manufacturing department, but production is overwhelmingly captive STADA rather than open-market CDMO. | Vršac, Serbia | Part of a pharma or industrial groupSTADA | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| HovioneFully integrated specialist CDMO: API, particle engineering/spray drying, drug product. FDA-inspected across 3 continents. | Loures, Portugal | Family-ownedVillax family | Tier 1 | not disclosed | Small-molecule API, Oral solid dose | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| PharmathenVertically integrated developer of complex drug-delivery tech offering CDMO/co-development: long-acting injectables, SR oral solids, ophthalmics. | Pallini, Greece | Private equityPartners Group | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Peptide | high |
| Rovi Pharma Industrial ServicesBest-known Spanish injectables fill-finish CDMO; performed fill-finish of the Moderna COVID vaccine. Rebranded 'Rois' (2024). | Madrid, Spain | ListedLaboratorios ROVI | Tier 1 | Group ROVI ~€1.0 bn | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| SopharmaListed Bulgarian pharma with a dedicated CDMO business unit: sterile/non-sterile liquids, oral solids/semi-solids, API, packaging/serialization; handles controlled substances. | Sofia, Bulgaria | Listed | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| Zentiva GroupLarge generics maker with an explicit B2B/CDMO arm (oral solids, sterile ampoules/vials, creams; APIs). Contract offering spans Prague and Bucharest. | Prague, Czechia | Private equityAdvent International | Tier 1 | ~€1.3 bn (group est.) | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Adamed Pharma | Pieńków, Poland | Family-owned | Tier 2 | >PLN 1.6 bn (2023) | Small-molecule API, Oral solid dose | medium |
| Adragos PharmaFSN Capital 'buy-and-build' roll-up acquiring sites from Sanofi/Fresenius Kabi. | Munich, Germany | Private equityFSN Capital | Tier 2 | n/d | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Aenova GroupMulti-site OSD/softgel/sterile group; acute data-silo profile across 14 sites. | Starnberg, Germany | Family-ownedKühne Holding | Tier 2 | n/d | Oral solid dose, Sterile fill-finish | medium |
| Antibiotice IașiState-controlled, BVB-listed; world leader in Nystatin API by fermentation. Explicit EU-GMP contract manufacturing plus sterile injectables, capsules, tablets. | Iași, Romania | State-ownedRomanian state (majority) | Tier 2 | not disclosed | Small-molecule API, Microbial and protein, Oral solid dose, Sterile fill-finish | high |
| APL (Apotek Produktion & Laboratorier)State-owned; dual mandate of extemporaneous compounding for Sweden plus a commercial CDMO arm. | Stockholm, Sweden | State-ownedSwedish State | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | high |
| Aptuit (Evotec)Integrated CMC CDMO of Evotec (Aptuit acquired 2017). GMP API drug substance + drug-product to commercial scale. | Verona, Italy | Part of a pharma or industrial groupEvotec | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | medium |
| BluepharmaIntegrated CRDMO. OSD capacity ~2bn units/year plus complex injectables and LNP work. FDA-inspected 5×. | Coimbra, Portugal | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Delpharm | Boulogne, France | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| Delpharm MilanoItalian operating CDMO plant of French group Delpharm; site acquired from Roche (2017); oral solid dosage + packaging. | Segrate, Italy | Part of a pharma or industrial groupDelpharm (France) | Tier 2 | not disclosed | Oral solid dose | medium |
| Doppel FarmaceuticiFull-service finished-dose CDMO: solids, semi-solids, liquids, sprays, and aseptic/terminally-sterilized injectable vials. | Cortemaggiore, Italy | Private equityTrilantic Europe | Tier 2 | €112.8 m (2024) | Oral solid dose, Sterile fill-finish | high |
| EthypharmHybrid specialty pharma + CDMO; CDMO arm specializes in controlled substances, HPAPIs and modified-release oral. | Saint-Cloud, France | Private equityPAI Partners | Tier 2 | €135 m (2024, SAS) | Oral solid dose, Small-molecule API | medium |
| FermionOrion's dedicated CDMO arm; small-molecule API CDMO (Phase I→commercial) incl. HPAPI/cytotoxic. Two FDA/EMA-approved API sites. | Espoo, Finland | Part of a pharma or industrial groupOrion Corporation | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | high |
| Fertin PharmaSpecialist CDMO for oral/intra-oral delivery (medicated gum, pouches, liquefiable tablets); leading NRT producer. Owned by PMI. | Vejle, Denmark | Part of a pharma or industrial groupPhilip Morris International | Tier 2 | not disclosed | Oral solid dose | high |
| Fine Foods & Pharmaceuticals N.T.M.Contract dev & manufacturing of oral solid forms for pharma and nutraceutical clients; serves 60+ pharma companies. Listed. | Zingonia-Verdellino, Italy | Listed | Tier 2 | not disclosed | Oral solid dose | high |
| GeneticLeading Italian CDMO in respiratory + ophthalmic. BFS sterile monodose, eye drops, nasal sprays, pMDI/DPI inhalers. | Fisciano, Italy | Private equityRenaissance Partners | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| GrindeksMajor Baltic pharma that formally launched CDMO services (2025): API dev/manufacturing incl. HPAPIs, plus solid/liquid/semi-solid FDFs. Sterile injectables via Kalceks. | Riga, Latvia | Family-ownedKirovs Lipmans (majority) | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina, Italy | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| Kern PharmaDedicated 'Production to Third Parties' line. 3rd-largest Spanish generics producer by volume; chemical plant synthesises APIs. | Terrassa, Spain | Family-ownedGrupo Indukern | Tier 2 | not disclosed | Oral solid dose, Small-molecule API | high |
| LabomarNutraceutical/food-supplement finished-dose CDMO (supplements, medical devices, pharmaceuticals) for third parties. | Istrana, Italy | Private equityCharterhouse Capital | Tier 2 | €135 m (2025) | Oral solid dose | low |
| Laboratorios León FarmaThird-party make-to-order manufacturer; dedicated hormonal OSD/contraceptives (tablets, caps, vaginal rings, semisolids). | Villaquilambre, Spain | Part of a pharma or industrial groupInsud Pharma | Tier 2 | not disclosed | Oral solid dose | high |
| Laboratorios LiconsaThird-party contract manufacturing. FDF specialist: tablets, capsules, pellets, soft-gel, creams, inhalers. | Azuqueca de Henares, Spain | Part of a pharma or industrial groupInsud Pharma | Tier 2 | not disclosed | Oral solid dose | high |
| Laboratorios NormonPrimarily own-product generics leader; offers CMO services via its International Division. CMO is a secondary line. | Tres Cantos, Spain | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | medium |
| Laboratorios SalvatCDMO division specializes in sterile BFS liquids and single-dose ophthalmic/otic/nasal formulations. | Barcelona, Spain | Family-ownedPeris family | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Meribel Pharma SolutionsFormed 2025 from Synerlab + 7 Recipharm sites; classic multi-site integration play. | London, United Kingdom | Private equityBlue Wolf | Tier 2 | ~€300 m est. | Sterile fill-finish, Oral solid dose | medium |
| Morpho (Alfasigma CDMO)Alfasigma's dedicated third-party CDMO unit (rebranded 'Morpho' 2024). Sterile injectables, lyophilized products, vaccines, oral solids. | Bologna, Italy | Part of a pharma or industrial groupAlfasigma | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars | high |
| NextPharma | London, United Kingdom | Private equity | Tier 2 | ~€229 m | Oral solid dose, Sterile fill-finish | medium |
| Olainfarm (Olpha)One of the largest Baltic pharma companies (rebranded Olpha); contract manufacturing and co-development across APIs, intermediates and solid FDFs. | Olaine, Latvia | Private equityAB City holding | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | high |
| Quotient SciencesFull-service third-party CDMO (drug substance/product + clinical). UK-HQ under European PE. | Nottingham, United Kingdom | Private equityPermira | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Peptide, Sterile fill-finish | low |
| Recipharm | Stockholm, Sweden | Private equityEQT | Tier 2 | €827 m (2024) | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| Reig JofreMarket leader in complex generics; CDMO covers sterile/lyophilized injectables plus beta-lactam antibiotics in segregated facilities. | Sant Joan Despí, Spain | Listed | Tier 2 | €339 m (2024) | Sterile fill-finish, Small-molecule API, Oral solid dose | high |
| Rottendorf Pharma~95-year-old foundation-owned CDMO focused on oral solid dosage forms. | Ennigerloh, Germany | Family-ownedRottendorf Foundation | Tier 2 | not disclosed | Oral solid dose | high |
| Saneca PharmaceuticalsSlovakia's largest pharma and a genuine API + FDF CDMO (carve-out of former Zentiva/Sanofi API business). Opiate/narcotic API specialist plus oral solids. | Hlohovec, Slovakia | Private equity | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Sever Pharma SolutionsSpecialist CDMO for high-potent (OEB6)/cytotoxic/hormonal drug products and polymer-based delivery. Formerly QPharma. | Malmö, Sweden | Family-ownedNordic Group (Paulsen family) | Tier 2 | not disclosed | Oral solid dose | high |
| Special Product's Line (SPL)Italian CDMO specialized in non-sterile finished dose: oral solids, liquids and semi-solids for 60+ clients. EU-GMP. | Anagni, Italy | Family-owned | Tier 2 | not disclosed | Oral solid dose | high |
| Tecnimede (Atlantic Pharma)Primarily own-product/generics group that also offers contract manufacturing (solids/semi-solids/liquids). CMO secondary. | Sintra, Portugal | Family-ownedTecnimede Group | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Unither PharmaceuticalsWorld leader in Blow-Fill-Seal sterile unit-dose liquids; also effervescent/oral formats. | Amiens, France | Private equityArdian | Tier 2 | €371 m (2022) | Sterile fill-finish, Oral solid dose | high |
| Vianex90+ yr firm; long-standing contract manufacturer (exclusive local/export production for MSD since 1983). Cephalosporins + solids/injectables. | Nea Erythraia, Greece | Family-ownedGiannakopoulos family | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Acino InternationalBranded-generics pharma that also runs a documented CDMO/contract-manufacturing arm for oral solid dosage forms. | Zurich, Switzerland | Part of a pharma or industrial groupArcera / ADQ | Tier 3 | not disclosed | Oral solid dose | medium |
| AdipharmPrivately-owned Bulgarian full-service CMO for solid dosage, semi-solids and oral liquids (dev, bulk, packaging incl. serialization). New €3.6M site (2022). | Sofia, Bulgaria | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| ArdenaNanomedicine/LNP + drug-substance/product + bioanalytical CDMO. | Ghent, Belgium | Private equityGHO Capital | Tier 3 | n/d | mRNA and LNP, Oral solid dose, Sterile fill-finish | medium |
| BDD PharmaSmall CDMO/CRO for modified/controlled-release oral formulation dev (proprietary OralogiK). More formulation-dev than commercial scale. | Glasgow, United Kingdom | Private equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| BimedaIrish family-owned global animal-health company; contract/private-label veterinary manufacturing (drenches, nutritional liquids, ecto-parasiticides). | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure, Italy | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| Chanelle PharmaIreland's largest indigenous generics maker (human + veterinary); explicitly offers CMO/CDMO services alongside own generics. | Loughrea, Ireland | Private equityExponent Private Equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Combino PharmGenerics developer that licenses out dossiers and offers third-party contract manufacturing, mainly via its Malta plant. | Sant Joan Despí, Spain | Family-ownedCorporación Medichem | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | medium |
| CoripharmaIndependent Icelandic generics CDMO (est. 2018) on the former Actavis site; solid oral dose, specialising in low-volume generics. Geothermal/hydro-powered. | Hafnarfjörður, Iceland | Private equity | Tier 3 | not disclosed | Oral solid dose | high |
| Custom Pharma ServicesFull-service oral-solid-dose CDMO (tablets/capsules/powders incl. HPAPI); process dev through commercial. Est. 1979. | Hove, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| EirGen PharmaIrish-HQ specialist HPAPI/oncology OSD CDMO (cytotoxic, genotoxic, steroidal) for external clients. Owned by OPKO (US). | Waterford, Ireland | Part of a pharma or industrial groupOPKO Health (US) | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| EscolitNewer (2021) Lithuanian CMO/CDMO for medicines and supplements — three full-cycle EU-GMP lines. Early stage; contract track record still thin. | Telšiai, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| FaveaFamily-run CDMO for nutraceuticals plus human/veterinary solid dosage (tablets, capsules, pellets). Pharma scope modest vs. supplements. | Kopřivnice, Czechia | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency. | Malmö, Sweden | Family-owned | Tier 3 | not disclosed | Oral solid dose, Peptide, Small-molecule API | high |
| Helsinn Birex PharmaceuticalsIrish-registered entity primarily making the Swiss parent's products; advertises third-party OSD + gel/cream contract manufacturing. Closer to captive site. | Dublin, Ireland | Part of a pharma or industrial groupHelsinn Group (Switzerland) | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | low |
| Hermes PharmaCDMO specialised in user-friendly oral forms: effervescent, orally-disintegrating granules, lozenges, instant drinks. | Wolfratshausen, Germany | Family-ownedHermes Arzneimittel | Tier 3 | not disclosed | Oral solid dose | medium |
| Iasis PharmaProvides CDMO/CMO services alongside own products (since 1985). Broad dosage forms; exports to 36 countries. | Koropi, Greece | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IdifarmaNiche small-molecule CDMO specialising in HPAPI/oncology small-batch manufacturing and spray-drying. | Pamplona, Spain | Part of a pharma or industrial groupArdena | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | high |
| Klocke Pharma-ServiceContract manufacturing/packaging of solid dosage plus aseptic liquids and lyophilisates. | Appenweier, Germany | Family-ownedKlocke Gruppe | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| LabianaCDMO/CMO for human and animal health; sterile liquids, non-sterile solids, sterile injectable + freeze-dried forms. BME Growth-listed. | Corbera de Llobregat, Spain | Listed | Tier 3 | €66 m (2024) | Sterile fill-finish, Oral solid dose | high |
| Laboratorios Alcalá Farma'Leading CDMO in Spain' (20+ yrs); broad dosage forms incl. soft-gel caps, stick-packs, sterile/injectable, lyophilised. Owned by Synerlab. | Alcalá de Henares, Spain | Part of a pharma or industrial groupSynerlab | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Laboratórios BasiPortuguese pharma (since 1956) offering contract manufacturing for injectables, gels, creams and oral solutions. CMO secondary. | Mortágua, Portugal | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Lamp San ProsperoItalian oral-solid-dose CDMO. Non-biologics tier-3 addition for completeness. | San Prospero, Italy | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Losan PharmaCDMO for solids, semi-solids, liquids, sachets and effervescent forms; FDA/ANVISA inspected. | Neuenburg am Rhein, Germany | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| LusomedicamentaManufacturer of solid, liquid and semi-solid dosage forms; explicitly lists contract manufacturing. Exports to 47 countries. | Queluz, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| MedinfarOperates a CMO/CDMO industrial unit (~20 yrs) alongside its own portfolio; finished dosage forms, galenic, packaging. | Amadora, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Meditop PharmaceuticalFamily-owned Hungarian SME making solid forms with own R&D; lists contract manufacturing but primarily own-product. | Pilisborosjenő, Hungary | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| mibe ArzneimittelDermapharm's main production site (tablets, sterile ampoules/lyo, ointments); primarily in-house, expanding third-party. | Brehna, Germany | Part of a pharma or industrial groupDermapharm Holding | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | low |
| Micro-SphereFounder-led CDMO specialising in spray drying (poorly-soluble drugs) and capsule filling, clinical to commercial. | Monteggio, Switzerland | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| NerPharMaHPAPI/oncology CDMO offering integrated drug substance + drug product: injectables and oral solids. EMA + FDA accredited. | Nerviano, Italy | Part of a pharma or industrial groupBenta Group (Lebanon) | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Small-molecule API | high |
| NextPharma GöttingenGerman solid-dosage sites (incl. allphamed Pharbil) of the privately held European NextPharma group. | Göttingen, Germany | Private equity | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | low |
| Ovelle PharmaceuticalsFamily-owned (since 1934). Own dermatology brands plus CMO/CDMO manufacturing of cosmetic, medical-device and licensed products. | Dundalk, Ireland | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Palla Pharma NorwayNorwegian maker of opiate-based APIs and finished dose (est. 1949). Primarily a merchant/own-product opiate-API producer rather than a client-driven CDMO. | Kragerø, Norway | Family-owned | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| Pinewood HealthcareIrish-HQ operating entity with a dedicated contract-manufacturing division (non-beta-lactam sachets/powders, oral liquids, creams). Owned by Wockhardt (India). | Ballymacarbry, Ireland | Part of a pharma or industrial groupWockhardt (India) | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| PrasfarmaCMO/CDMO specialized in cytostatics, HPAPI and oncology; aseptic fill/lyophilization plus solid forms. Annex-1. | Cerdanyola del Vallès, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Purna PharmaceuticalsNon-sterile CDMO: solids, semi-solids and liquids; OEB 1-5. | Puurs, Belgium | Private equityAmpersand Capital | Tier 3 | not disclosed | Oral solid dose | high |
| Quay Pharma (SGS)Formulation-development + clinical/commercial CDMO HQ'd in Deeside, Wales. Acquired by SGS (Switzerland). | Deeside, United Kingdom | Part of a pharma or industrial groupSGS | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Rosemont PharmaceuticalsOral-liquid-medicines specialist (~60 yrs); primarily branded/specials but offers contract manufacturing/CDMO services. | Leeds, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | medium |
| ScanpharmGMP family-owned combined CMO and contract laboratory (est. 1951); tablets incl. packaging, serialization, testing; small own niche-generics portfolio. | Birkerød, Denmark | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| SkyepharmaComplex oral-solid-dose specialist (modified-release, multi-layer/press-coated tablets). Management-owned. | Saint-Quentin-Fallavier, France | Family-ownedOléron Pharma | Tier 3 | ~€20 m+ (site) | Oral solid dose | high |
| Upperton Pharma SolutionsSpray-drying specialist CDMO: formulation + dosage-form dev for oral, nasal, pulmonary and sterile forms (small molecules + biologics). | Nottingham, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | high |
| ValentisLithuanian group offering contract manufacturing of tablets, capsules, liquids/shots and powders plus primary/secondary packaging. | Kaunas, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| Wasdell GroupUK contract packaging + CDMO (solid/non-sterile dosage, clinical + commercial). Wound down Irish operations in 2024 — verify current status. | Swindon, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)